MENLO PARK, Calif.— November 17, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure (IOP) – a meaningful and independent risk factor for the progression of glaucoma.
OMNI is cleared by the U.S. Food and Drug Administration (FDA) and CE-Marked for canaloplasty followed by trabeculotomy to reduce IOP in adult patients with primary open-angle glaucoma (POAG) (FDA) and open-angle glaucoma (CE).* Sight Sciences intends to further develop OMNI and seek regulatory clearance for expanded indications.
The importance of IOP reduction to limit…